BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:macupatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of macupatide\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07215559-245@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:macupatide: Phase 2 readout est. (NCT07215559)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Study of Macupatide (
 LY3532226) and Eloralintide (LY3841136)\, Alone or in Combination\, in Adu
 lts With Obesity or Overweight and With Type 2 Diabetes\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/macupatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07215559
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765511-245@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:macupatide: Phase 1 readout est. (NCT07765511)
DESCRIPTION:macupatide\, phase 1\, Obesity.\nStudy: A Study of Macupatide (
 LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabe
 tes\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/macupatide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07765511
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-245@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:macupatide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Master Protocol Study
  (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult P
 articipants With Obesity or Overweight\nEstimated primary completion: Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/macupatid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 143956
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589608-245@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:macupatide: Phase 2 readout est. (NCT07589608)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Study to Investigate 
 Weight Management With Macupatide and Eloralintide\, Alone or in Combinati
 on\, in Adult Participants With Obesity or Overweight\nEstimated primary c
 ompletion: September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/macupatide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07589608
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
